AMGEN INC

AMGN
Biological products no disgnostic substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

14 more years with Pro

AMGEN INC back to 2009, every line as filed.

Create a free account
USD ($)
$ in Millions 		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Cash flows from operating activities:
                  
Net income
$ 8,743
$ 7,711
$ 4,090
$ 6,717
Noncash adjustments to reconcile net income to net cash provided by operating activities:
                  
Depreciation, amortization and other
4,667
5,167
5,592
4,071
Impairment of intangible assets
400
1,200
-
-
Write-off of acquired in-process research and development
-
-
-
-
Stock-based compensation expense
492
494
530
431
Deferred income taxes
(516)
(721)
(1,228)
(1,273)
Acquired in-process research and development
-
-
-
0
Adjustments for equity method investments
-
-
(10)
11
Loss on divestiture
-
-
0
0
(Gains) losses on equity securities
(1,022)
(2,064)
159
(1,565)
Property, plant and equipment impairments
-
-
-
-
Dividend received from equity investee
-
-
-
-
Other items, net
230
149
(8)
563
Changes in operating assets and liabilities, net of acquisitions:
                  
Trade receivables, net
(1,533)
(2,676)
441
(1,015)
Inventories
346
886
2,532
491
Other assets
(1,182)
(1,267)
(652)
(564)
Accounts payable
(157)
428
312
(402)
Accrued income taxes, net
185
(2,068)
(1,011)
(1,031)
Long-term tax liabilities
297
311
(492)
371
Accrued liabilities
491
499
92
-
Accrued sales incentives and allowance
1,230
2,065
1,194
935
Long-term tax liability
-
-
-
-
Legal reserve
-
-
-
-
Other liabilities
(193)
(156)
(51)
731
Other accrued liabilities
-
-
-
-
Deferred revenue
-
-
-
-
Net cash provided by operating activities
12,478
9,958
11,490
8,471
Cash flows from investing activities:
                  
Cash paid for acquisitions, net of cash acquired
(53)
(53)
0
(26,989)
Purchases of marketable securities
-
-
0
(1)
Purchases of intangible assets
-
-
-
-
Proceeds from sales of marketable securities
0
0
0
1,123
Proceeds from maturities of marketable securities
0
0
0
550
Purchases of property, plant and equipment
(2,303)
(1,858)
(1,096)
(1,112)
Purchases of equity method investments
-
-
-
-
Proceeds from Divestiture of Businesses, Net of Cash Divested
-
-
-
-
Proceeds from sales of property, plant and equipment
-
-
-
-
Change in restricted investments, net
-
-
-
-
Other
(36)
(32)
50
225
Net cash used in investing activities
(2,392)
(1,943)
(1,046)
(26,204)
Cash flows from financing activities:
                  
Net proceeds from issuance of debt
-
0
0
27,777
Extinguishment of debt
(314)
(683)
(659)
(647)
Repayment of debt
(2,333)
(5,000)
(3,600)
(1,454)
Net proceeds from issuance of commercial paper
-
-
-
-
Repayments of commercial paper
-
-
-
-
Repurchases of common stock
0
0
(200)
0
Dividends paid
(5,285)
(5,124)
(4,832)
(4,556)
Settlement of contingent consideration obligations
-
-
-
-
Net proceeds from issuance of common stock in connection with the Company’s equity award programs
-
-
-
-
Settlement of contingent consideration obligations
-
-
-
-
Withholding taxes arising from shares withheld for share-based payments
-
-
-
-
Other
(157)
(52)
(124)
(72)
Net cash (used in) provided by financing activities
(4,125)
(10,859)
(9,415)
21,048
(Decrease) increase in cash and cash equivalents
-
-
-
-
(Decrease) increase in cash and cash equivalents
$ 5,961
$ (2,844)
$ 1,029
$ 3,315